Payment overview · 2025
General Payments
$771.67
9 reported records · 7 companies
Healthcare provider profile · identity verified
Andrea D Oliver, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CARTHAGE, TX · NPI 1407928658
Verified facts
What the public records show
CMS Open Payments records show Andrea D Oliver, APRN received $771.67 in general payments during 2025 across 9 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 36.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $284.59 | 36.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $125.00 | 16.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 16.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $125.00 | 16.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $70.58 | 9.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.83 | 2.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.67 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $771.67 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $284.59 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $70.58 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 256 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 49 |
| Metformin Hcl | Metformin Hcl | 184 | 54 |
| Mounjaro | Tirzepatide | 145 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 37 |
| Tramadol Hcl | Tramadol Hcl | 117 | 35 |
| Gabapentin | Gabapentin | 97 | 35 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 91 | 19 |
| Trulicity | Dulaglutide | 86 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 31 |
| Pregabalin | Pregabalin | 72 | 21 |
| Lisinopril | Lisinopril | 70 | 22 |
| Carvedilol | Carvedilol | 67 | 16 |
| Furosemide | Furosemide | 63 | 23 |
| Allopurinol | Allopurinol | 62 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 17 |
| Trazodone Hcl | Trazodone Hcl | 61 | 21 |
| Jardiance | Empagliflozin | 58 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 19 |
| Omeprazole | Omeprazole | 52 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 20 |
| Alprazolam | Alprazolam | 51 | suppressed |
| Simvastatin | Simvastatin | 47 | 11 |
| Bupropion Xl | Bupropion Hcl | 46 | suppressed |
| Meloxicam | Meloxicam | 45 | 17 |
| Spironolactone | Spironolactone | 45 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 12 |
| Celecoxib | Celecoxib | 43 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 18 |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | 15 |
| Potassium Chloride | Potassium Chloride | 43 | 13 |
| Buprenorphine | Buprenorphine | 41 | suppressed |
| Eliquis | Apixaban | 39 | 11 |
| Famotidine | Famotidine | 39 | 18 |
| Methylprednisolone | Methylprednisolone | 39 | 25 |
| Clonazepam | Clonazepam | 36 | 11 |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | 13 |
| Prednisone | Prednisone | 33 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Eszopiclone | Eszopiclone | 32 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Losartan Potassium | Losartan Potassium | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | 13 |
| Irbesartan | Irbesartan | 31 | 11 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 19 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 16 |
| Mirtazapine | Mirtazapine | 28 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | 11 |
| Vilazodone Hcl | Vilazodone Hcl | 28 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Linzess | Linaclotide | 23 | 11 |
| Ramipril | Ramipril | 23 | suppressed |
| Azithromycin | Azithromycin | 21 | 17 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Diazepam | Diazepam | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 13 | 13 |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $771.67 · 9 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | BREZTRI, CAPLYTA, GEMTESA, JARDIANCE, Korlym, TRELEGY ELLIPTA, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error